Description: Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Home Page: www.nkartatx.com
NKTX Technical Analysis
6000 Shoreline Court
South San Francisco,
CA
94080
United States
Phone:
415 582 4923
Officers
| Name | Title |
|---|---|
| Mr. Paul J. Hastings | CEO, Pres & Director |
| Dr. Nadir Mahmood Ph.D. | Chief Financial & Bus. Officer |
| Dr. Ralph Brandenberger Ph.D. | Chief Technical Officer |
| Dr. James Trager Ph.D., Ph.D. | Chief Scientific Officer |
| Ms. Yvonne Li M.B.A. | Chief Admin. Officer |
| Mr. Greg Mann | VP of Public Affairs and Investor Relations |
| Dr. Alicia J. Hager | Chief Legal Officer & Corp. Sec. |
| Dr. David R. Shook M.D. | VP of Clinical Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9096 |
| Price-to-Sales TTM: | 999999.9999 |
| IPO Date: | 2020-07-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 146 |